Carlsmed (CARL)

Carlsmed’s technology is used in lumbar and cervical spine fusion, procedures performed to stabilize the spine and address conditions such as degenerative disc disease, deformity, and other structural problems. The company’s process typically involves preoperative planning based on patient imaging, followed by the design and manufacture of customized interbody implants intended to match the surgical plan. This approach aims to improve alignment, fit, and procedural consistency for spine surgeons.

The company sells primarily to hospitals and ambulatory surgical centers, placing it within the broader orthopedic and neurosurgical device market. As a commercial-stage business, Carlsmed is beyond early research and development, but its growth depends on surgeon adoption, clinical outcomes, reimbursement dynamics, manufacturing execution, and competition from larger spine device companies with established distribution networks.

Carlsmed operates as a single reportable business centered on the design, production, and marketing of its personalized spine platform. Its distinctive position lies in applying AI-enabled planning and custom implant manufacturing to a category where precision and patient-specific anatomy are especially important. The company reflects a broader trend in medtech toward software-guided procedures, data-driven surgical workflows, and implants tailored to individual patients.